This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority.
NEW YORK – Illumina has proposed offering perpetual, royalty-free licenses to Pacific Biosciences' intellectual property to competitors in the sequencing market in an effort to appease UK regulators who have threatened to block Illumina's planned acquisition of PacBio.